Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
AstraZeneca
Healthtrust
Citi
Mallinckrodt
Covington
Fish and Richardson
Farmers Insurance

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020800

« Back to Dashboard

NDA 020800 describes TWINJECT 0.3, which is a drug marketed by Impax Labs Inc and is included in one NDA. It is available from eight suppliers. There are two patents protecting this drug. Additional details are available on the TWINJECT 0.3 profile page.

The generic ingredient in TWINJECT 0.3 is epinephrine. There are nineteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.
Summary for 020800
Tradename:TWINJECT 0.3
Applicant:Impax Labs Inc
Ingredient:epinephrine
Patents:3
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020800
Suppliers and Packaging for NDA: 020800
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ADRENACLICK epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800 NDA AUTHORIZED GENERIC Impax Generics 0115-1694 N 0115-1694-30
ADRENACLICK epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800 NDA AUTHORIZED GENERIC Impax Generics 0115-1694 N 0115-1694-49

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUSStrengthEQ 0.3MG/DELIVERY
Approval Date:May 30, 2003TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Jan 18, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Feb 4, 2025Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUSStrengthEQ 0.15MG/DELIVERY
Approval Date:May 28, 2004TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Jan 18, 2025Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 020800

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Impax Labs Inc ADRENACLICK epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-003 Nov 25, 2009 ➤ Sign Up ➤ Sign Up
Impax Labs Inc ADRENACLICK epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-004 Nov 25, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Covington
Express Scripts
Citi
Julphar
McKinsey
Moodys
Cipla
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.